Pharmaco - Press Releases

Date	Title	Company
30-Jul-2021	Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate	Takeda
30-Jul-2021	Amgen Appoints S. Omar Ishrak To Board Of Directors	Amgen
30-Jul-2021	Polyphor to extend period for its strategic evaluation by up to four weeks	Polyphor AG
30-Jul-2021	Fresenius Medical Care AG & Co. KGaA reports results in line with expectations for the second quarter and confirms 2021 outlook	Fresenius Medical Care AG & Co. KGaA
30-Jul-2021	Cosmo Half-Year Report 2021	Cosmo Pharmaceuticals N.V.
29-Jul-2021	Scipher Medicine Increases Patient Access for PrismRA® by Expanding Intended Use in Autoimmune Patients	B3C newswire
29-Jul-2021	Invitation: Straumann Group 2021 half-year financial results webcast	Straumann Holding AG
29-Jul-2021	SIGA announces collaboration with Oxford University to support expanded access protocol for use of TPOXX® (Tecovirimat) to treat monkeypox in Central African Republic	SIGA Technologies, Inc.
29-Jul-2021	Macomics, the Macrophage-based Drug Discovery company, secures £4.24m expansion financing, and appoints CEO, CSO and VP Immunology	Macomics Ltd
29-Jul-2021	Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI	Sanofi
29-Jul-2021	Birmingham cancer project enters Immuno-oncology Alliance	Institute of Immunology and Immunotherapy
29-Jul-2021	NRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation to Progress Parkinson’s Programme	NRG Therapeutics
29-Jul-2021	Innovative gene therapy programme paves the way for new treatments for neurodegenerative diseases	Cell and Gene Therapy Catapult
29-Jul-2021	4D pharma announces USD 30 million credit facility with Oxford Finance	4D pharma
29-Jul-2021	Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients	Sanofi
29-Jul-2021	atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs	atai Life Sciences
29-Jul-2021	Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases	Complix
29-Jul-2021	STADA and Sanofi strike consumer healthcare distribution agreement in selected countries in Europe	STADA and Sanofi
29-Jul-2021	LISTED FOR 20TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT	EISAI
29-Jul-2021	U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)	Takeda